In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption

Item

http://www.wikidata.org/entity/Q35836035

Q35836035

about

Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?Smarter drugs emerging in pancreatic cancer therapy.HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells New targeted therapies in pancreatic cancer.Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial Introduction to monoclonal antibodies.HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2 Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab Cancer subclonal genetic architecture as a key to personalized medicine.Polymer nanoparticulate drug delivery and combination cancer therapy.Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling.In vitro evaluation of HPMA-copolymers targeted to HER2 expressing pancreatic tumor cells for image guided drug delivery.Epidermal growth factor receptor targeting alters gene expression and restores the adhesion function of cancerous cells as measured by single cell force spectroscopy.Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.Emerging trends in the immunotherapy of pancreatic cancer.Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin β1-driven Src-Akt bypass signaling.[The HER3/ERBB3 receptor: the dark side of the ERBB planet].Global Approaches to Understanding Protein Kinase Functions

P2860

Q30410012-CCF363BA-1858-4992-A2A6-6C4AC1B5EFF4 Q30416415-B0CC4633-32E8-4217-AC16-EA3A414A3FEC Q30422319-621E0CCA-71A9-4D64-A5C3-DFB4E7F67849 Q33361738-731C5F40-3C6F-4687-89A6-F939FAC00601 Q34410212-7FD40B41-9AF8-4F2C-968D-8521C962B2B3 Q35201923-7135E556-8C58-435B-B857-FC593885D7A5 Q35651453-2046838D-670A-4223-9F30-6DACA49A43DE Q35828693-4854854E-F7E6-4E9C-A99C-0FA7C4F07169 Q36050008-FEFD40C8-FF76-4C75-B012-C552CDDA8086 Q36544773-6CAD56D5-D2AC-4943-85A8-04A7D096B39E Q36545789-B0650953-6744-44E4-840F-EF1678E0667E Q36640265-2A2C2344-C017-47CC-874A-F7225AE416B5 Q36797398-F806F863-E2BA-4222-BCA9-5C5E30980A71 Q37191934-78A64AE5-F615-43AA-9C89-7577291F8DBF Q37285565-C2A3BCB6-2841-466A-A885-EE4CC132A661 Q37448116-8550DA3E-C84D-4BD5-94DF-86EED7222761 Q38059506-B0EB9155-34CE-482B-A18E-EC418896E25F Q38563897-C5C688F1-21AD-4A50-ACF4-B2E922CD516E Q38762325-40FACB04-15B0-43E8-A0C4-74FF0396AD06 Q38868047-89EA5C7F-4F43-4F70-9628-CF2BFAFB6438 Q39011809-E833975C-5085-4CD7-A8D5-8D22CEF23A77 Q39095666-2121525A-E288-4E59-93D6-ADF795926565 Q39328784-8F2C9EAD-81F0-47D2-A550-EC7DBBEBAF7D Q41850545-D286E59B-F43E-4A74-9CB8-4A9536F0D001 Q41879186-00F76E20-EF82-4588-B0D1-D05FFC1AD451 Q45968005-2422A995-AF48-452D-9A94-E252B31A6E6F Q47248817-AD158ACE-E24A-4236-8E3A-80FE3BC7AF27 Q48949989-4F5DF5A5-1A41-4A28-8933-42F7EBAB8AA1 Q54266767-3C55AABB-72D5-439F-BFF1-090DCB991F76 Q57833109-5858FFED-0743-41E9-8FF3-FB7B6180AE09

P2860

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption

Item

http://www.wikidata.org/entity/Q35836035

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

In pancreatic carcinoma, dual ...... ulation and dimers' disruption

@ast

In pancreatic carcinoma, dual ...... ulation and dimers' disruption

@en

type

Item

label

In pancreatic carcinoma, dual ...... ulation and dimers' disruption

@ast

In pancreatic carcinoma, dual ...... ulation and dimers' disruption

@en

prefLabel

In pancreatic carcinoma, dual ...... ulation and dimers' disruption

@ast

In pancreatic carcinoma, dual ...... ulation and dimers' disruption

@en

P1476

In pancreatic carcinoma, dual ...... ulation and dimers' disruption

@en

P2093

André Pèlegrin

http://www.w3.org/2001/XMLSchema#string

Bruno Robert

http://www.w3.org/2001/XMLSchema#string

Caroline Bascoul-Mollevi

http://www.w3.org/2001/XMLSchema#string

Christel Larbouret

http://www.w3.org/2001/XMLSchema#string

David Azria

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Campigna

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Mach

http://www.w3.org/2001/XMLSchema#string

Mickaël Coelho

http://www.w3.org/2001/XMLSchema#string

Nadège Gaborit

http://www.w3.org/2001/XMLSchema#string

P2860

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Untangling the ErbB signalling network

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

A quantitative analysis of kinase inhibitor selectivity

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.

Pancreatic cancer: molecular pathogenesis and new therapeutic targets.

Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies

Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.

P304

121-130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.111602

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thierry Chardès

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221724490

http://www.w3.org/2001/XMLSchema#string

P698

22431920

http://www.w3.org/2001/XMLSchema#string

P921

cetuximab

P932

3306257

http://www.w3.org/2001/XMLSchema#string

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption

about

P2860

P2860

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932